Literature DB >> 8789188

Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411.

P Furet1, G Caravatti, N Lydon, J P Priestle, J M Sowadski, U Trinks, P Traxler.   

Abstract

A model for the binding mode of the potent protein kinase inhibitor staurosporine is proposed. Using the information provided by the crystal structure of the cyclic-AMP-dependent protein kinase, it is suggested that staurosporine, despite a seemingly unrelated chemical structure, exploits the same key hydrogen-bond interactions as ATP, the cofactor of the protein kinases, in its binding mode. The structure-activity relationship of the inhibitor and a docking analysis give strong support to this hypothesis. The selectivity of the dianilinophthalimide inhibitor CGP 52411 towards the EGF-receptor protein tyrosine kinase is rationalized on the basis of the model. It is proposed that this selectivity originates in the occupancy, by one of the anilino moieties of the inhibitor, of the region of the enzyme cleft that normally binds the ribose ring of ATP, which appears to possess a marked lipophilic character in this kinase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8789188     DOI: 10.1007/bf00124317

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  23 in total

1.  Characterization of receptor tyrosine-specific protein kinases by the use of inhibitors. Staurosporine is a 100-times more potent inhibitor of insulin receptor than IGF-I receptor.

Authors:  Y Fujita-Yamaguchi; S Kathuria
Journal:  Biochem Biophys Res Commun       Date:  1988-12-30       Impact factor: 3.575

2.  Predictor for sulfur-aromatic interactions in globular proteins.

Authors:  R S Morgan; J M McAdon
Journal:  Int J Pept Protein Res       Date:  1980-02

3.  A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization.

Authors:  S Omura; Y Iwai; A Hirano; A Nakagawa; J Awaya; H Tsuchya; Y Takahashi; R Masuma
Journal:  J Antibiot (Tokyo)       Date:  1977-04       Impact factor: 2.649

4.  Assignment of conserved amino acid residues to the ATP site in the protein kinase domain of the receptor for epidermal growth factor.

Authors:  S Vogel; W Freist; J Hoppe
Journal:  Eur J Biochem       Date:  1986-02-03

5.  Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor.

Authors:  J Zheng; D R Knighton; L F ten Eyck; R Karlsson; N Xuong; S S Taylor; J M Sowadski
Journal:  Biochemistry       Date:  1993-03-09       Impact factor: 3.162

6.  Crystal structure of the tyrosine kinase domain of the human insulin receptor.

Authors:  S R Hubbard; L Wei; L Ellis; W A Hendrickson
Journal:  Nature       Date:  1994 Dec 22-29       Impact factor: 49.962

7.  Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase.

Authors:  U Trinks; E Buchdunger; P Furet; W Kump; H Mett; T Meyer; M Müller; U Regenass; G Rihs; N Lydon
Journal:  J Med Chem       Date:  1994-04-01       Impact factor: 7.446

8.  Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.

Authors:  R A Bit; P D Davis; L H Elliott; W Harris; C H Hill; E Keech; H Kumar; G Lawton; A Maw; J S Nixon
Journal:  J Med Chem       Date:  1993-01-08       Impact factor: 7.446

Review 9.  Signal-transduction therapy. A novel approach to disease management.

Authors:  A Levitzki
Journal:  Eur J Biochem       Date:  1994-11-15

10.  4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.

Authors:  E Buchdunger; U Trinks; H Mett; U Regenass; M Müller; T Meyer; E McGlynn; L A Pinna; P Traxler; N B Lydon
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more
  10 in total

1.  A hybrid approach for addressing ring flexibility in 3D database searching.

Authors:  J Sadowski
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

Review 2.  Translational hematology.

Authors:  Klaus Geissler
Journal:  Wien Med Wochenschr       Date:  2014-09-10

3.  Selectivity analysis of 5-(arylthio)-2,4-diaminoquinazolines as inhibitors of Candida albicans dihydrofolate reductase by molecular dynamics simulations.

Authors:  V M Gokhale; V M Kulkarni
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

4.  Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.

Authors:  Aleem Gangjee; Ying Zhao; Sudhir Raghavan; Michael A Ihnat; Bryan C Disch
Journal:  Bioorg Med Chem       Date:  2010-05-25       Impact factor: 3.641

5.  Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors.

Authors:  Amany Belal; Nagwa M Abdel Gawad; Ahmed B M Mehany; Mohammed A S Abourehab; Hazem Elkady; Ahmed A Al-Karmalawy; Ahmed S Ismael
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

6.  Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors.

Authors:  Mari Ikuta; Maria Kornienko; Noel Byrne; John C Reid; Shinji Mizuarai; Hidehito Kotani; Sanjeev K Munshi
Journal:  Protein Sci       Date:  2007-10-26       Impact factor: 6.725

7.  Drug discovery prospect from untapped species: indications from approved natural product drugs.

Authors:  Feng Zhu; Xiao Hua Ma; Chu Qin; Lin Tao; Xin Liu; Zhe Shi; Cun Long Zhang; Chun Yan Tan; Yu Zong Chen; Yu Yang Jiang
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

8.  New Benzimidazole-, 1,2,4-Triazole-, and 1,3,5-Triazine-Based Derivatives as Potential EGFRWT and EGFRT790M Inhibitors: Microwave-Assisted Synthesis, Anticancer Evaluation, and Molecular Docking Study.

Authors:  Heba E Hashem; Abd El-Galil E Amr; Eman S Nossier; Manal M Anwar; Eman M Azmy
Journal:  ACS Omega       Date:  2022-02-18

9.  Design, synthesis, in vitro biological assessment and molecular modeling insights for novel 3-(naphthalen-1-yl)-4,5-dihydropyrazoles as anticancer agents with potential EGFR inhibitory activity.

Authors:  Wagdy M Eldehna; Mahmoud A El Hassab; Zainab M Elsayed; Tarfah Al-Warhi; Hazem Elkady; Mahmoud F Abo-Ashour; Mohammed A S Abourehab; Ibrahim H Eissa; Hatem A Abdel-Aziz
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

10.  Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M.

Authors:  Ahmed A Gaber; Mohamed Sobhy; Abdallah Turky; Hanan Gaber Abdulwahab; Ahmed A Al-Karmalawy; Mostafa A Elhendawy; Mohamed M Radwan; Eslam B Elkaeed; Ibrahim M Ibrahim; Heba S A Elzahabi; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.